U-Factor Co., Ltd. has successfully invented a miRNA marker to measure the solution’s therapeutic effect

～ This invention marks a significant contribution to stabilizing the quality of U-Factor® Solution～

U-Factor Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; CEO: Hidehiro Ijima, hereinafter referred to as “the Company”), a venture in the field of drug discovery, has developed a novel miRNA marker that measures the therapeutic efficacy of U-Factor® Solution, derived from deciduous dental pulp stem cell culture supernatant. This breakthrough addresses a critical challenge in the biopharmaceutical industry, significantly contributing to the stabilization of the solution’s quality. In line with our goal of ensuring the highest quality and consistent supply of U-Factor® Solution, the Company will initiate collaborations for joint research using this invention starting November 1, 2024 (Friday).

For inquiries regarding joint research, please contact us here：https://u-factor.com/inquiry/partnership/

【Patent Overview】

Patent No.: JP 7474020
Patent Registration Date: April 16, 2024
Patent Holder: U-Factor Co., Ltd.
Patent Title: The determination method and a manufacturing method of the culture supernatant of therapeutic effect and the dental pulp stem cells of the culture supernatant of dental pulp stem cells.
　　　　　 

【Current Collaborative Research Partners】

For more information on our research partners, click here：https://u-factor.com/joint/

【About U-Factor® Solution】

Our company has developed a highly purified culture supernatant, derived from the process of culturing stem cells, using our proprietary technology. We have named this solution U-Factor® Solution (Registration No.: 6396893). The solution is rich in cytokines, which are proteins with physiological activity secreted by stem cells. The effectiveness of this solution was first discovered by Professor Minoru Ueda, a director at our company and Professor Emeritus of Nagoya University Graduate School of Medicine (M. Ueda, et al., Neuroscience, 2015). We have since refined and further purified U-Factor® Solution through specialized methods, and we believe it holds immense potential in terms of both safety and efficacy.

【Comments on This Invention】

【About U-Factor Co., Ltd.】

Founded: March 2020
CEO: Hidehiro Ijima (President and CEO)
Location: 7-11 Rokubancho, Chiyoda-ku, Tokyo, ESCALIER Rokubancho 1F
Website: https://u-factor.com/
Business Overview: U-Factor Co., Ltd. is dedicated to the formulation of therapeutic drugs targeting intractable diseases such as Alzheimer’s-type dementia using U-Factor® Solution. There are numerous diseases for which no effective treatment has been established. Our company is committed to addressing these unmet medical needs* by developing new drugs utilizing U-Factor® Solution.

*Unmet Medical Needs: Refers to medical needs for diseases where no effective treatment has yet been found.

【Contact Information】

U-Factor Co., Ltd.
Phone: 03-5357-1580
Email: info@u-factor.com